News – Page 409 – Endpoints News

GSK, CureVac forge ahead with mid-stage plans for flu, Covid mRNA vaccines

3 years ago

Betting on cell memory, AbbVie pays Immunome $30M upfront to further antibody research

3 years ago

Six years later, SEC drops claims of accounting fraud against biotech exec

3 years ago

An antibiotics biotech begins wind-down, lays off nearly all workers

3 years ago

Synthekine nabs $100M to boost IL-2 programs after rivals hit setbacks

3 years ago

Updated: Sickle cell gene editing startup halts trial after flagging serious side effect in first patient

3 years ago

Biogen names development chief as it braces for lecanemab decision; Zymeworks CMO is shown the door

3 years ago

Pfizer tags early research programs for 'externalization' as it narrows focus in rare disease, cancer

3 years ago

Updated: Stealth biotech Perceive raises $78M from J&J and Deerfield, says little about eye disease programs

3 years ago

Moderna pivots from a buyout to a platform tech alliance as its struggling partner scores another marquee ally

3 years ago

Fate and J&J end deal that once promised $3B in milestones; biotech cuts staff

3 years ago

On in vivo cell therapy quest, Takeda-backed Ensoma buys a CRISPR upstart and bags $85M

3 years ago

Only 1 of 25 cancer drug developers fairly included minority patients over five-year window, BMJ analysis finds

3 years ago

Intellia plots pivotal trials for lead programs as it lays out key objectives

3 years ago

After an EU approval, AstraZeneca and Sanofi's RSV antibody seeks an FDA thumbs-up in Q3

3 years ago

Bausch + Lomb tackles glaucoma awareness and research funding with nonprofit partner in new campaign

3 years ago

Ready for takeoff: J&J's consumer health unit Kenvue files for official separation

3 years ago

Manufacturing roundup: Lotte nabs BMS facility in New York; Alcami acquisition complete

3 years ago

Sarepta marches forward with its potential DMD gene therapy and an expanded Catalent manufacturing deal

3 years ago

Takeda touts interim PhIII data of enzyme replacement therapy for rare blood disease

3 years ago

Y-mAbs cuts 35% of staff; Genentech re-ups Nimble deal; Landos shifts focus; and more

3 years ago

The C-suite shuffle: Oncopeptides, Zymeworks replace execs to start 2023

3 years ago

Amgen kicks off 2023 dealmaking with busy ADC upstart Synaffix

3 years ago

Chris Viehbacher once again sets out to revamp R&D at a major biopharma. The last try led to his ouster

3 years ago

First page Previous page 406 407 408409410 411 412 Next page Last page